JPRN-UMIN000023761已完成1 期
A phase I study of osimertinib with bevacizumab and randomized phase II study of osimertinib with or without bevacizumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs. (WJOG8715L) - Phase I/II study of osimertinib with bevacizumab (WJOG8715L)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 87
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Subjects with interstitial lung disease 2. Subjects with high risk of bleeding 3. Positive test for hepatitis B virus antigen
研究者
相似试验
已完成
不适用
A Phase Ib study of osimertinib with ramucirumab in EGFR mutated lung adenocarcinoma patients. (LY3009806-IIT-01)JPRN-UMIN000030142Wakayama Medical University6
已完成
2 期
Osimertinib combined bevacizumab in untreated epidermal growth factor receptor mutaeted non-small-cell lung cancer patients with malignant pleural and/or pericardial effusion -phase II trialadvanced/recurrent non-small cell lung cancer (NSCLC)JPRN-UMIN000028071Clinical Research Support Center Kyushu31
已完成
1 期
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersEGFR-mutant Lung CancersNon-small Cell Lung CancerNCT02803203Memorial Sloan Kettering Cancer Center49
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in combination with Platinum-pemetrexed in patients with EGFR-mutated Advanced non-small cell Lung cancer.on-squamous non-small cell lung cancerJPRN-jRCTs031180226Kobayashi Kunihiko66
进行中（未招募）
1 期
A research study to compare the combined treatment of osimertinib and bevacizumab with osimertinib treatment alone in patients with lung cancer that has progressed or spread to other parts of the body (metastatic) and with confirmed specific gene mutations (changes) in the epithelial growth factor receptor (EGFR)EUCTR2016-002029-12-NLETOP (European Thoracic Oncology Platform)154